GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirati Therapeutics Inc (NAS:MRTX) » Definitions » PS Ratio

Mirati Therapeutics (Mirati Therapeutics) PS Ratio : 93.62 (As of May. 10, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Mirati Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Mirati Therapeutics's share price is $58.70. Mirati Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.63. Hence, Mirati Therapeutics's PS Ratio for today is 93.62.

The historical rank and industry rank for Mirati Therapeutics's PS Ratio or its related term are showing as below:

MRTX' s PS Ratio Range Over the Past 10 Years
Min: 28.25   Med: 212.6   Max: 3801.59
Current: 93.62

During the past 13 years, Mirati Therapeutics's highest PS Ratio was 3801.59. The lowest was 28.25. And the median was 212.60.

MRTX's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.15 vs MRTX: 93.62

Mirati Therapeutics's Revenue per Sharefor the three months ended in Sep. 2023 was $0.25. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.63.

During the past 12 months, the average Revenue per Share Growth Rate of Mirati Therapeutics was 194.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 35.40% per year.

During the past 13 years, Mirati Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 49.30% per year. The lowest was -75.70% per year. And the median was 3.45% per year.

Back to Basics: PS Ratio


Mirati Therapeutics PS Ratio Historical Data

The historical data trend for Mirati Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirati Therapeutics PS Ratio Chart

Mirati Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 101.48 1,447.87 737.05 105.53 205.02

Mirati Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 327.89 205.02 111.32 76.55 69.47

Competitive Comparison of Mirati Therapeutics's PS Ratio

For the Biotechnology subindustry, Mirati Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirati Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirati Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Mirati Therapeutics's PS Ratio falls into.



Mirati Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Mirati Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=58.70/0.627
=93.62

Mirati Therapeutics's Share Price of today is $58.70.
Mirati Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.63.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Mirati Therapeutics  (NAS:MRTX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Mirati Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Mirati Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mirati Therapeutics (Mirati Therapeutics) Business Description

Traded in Other Exchanges
Address
3545 Cray Court, San Diego, CA, USA, 92121
Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer. It operates in a single geographical segment being the United States.
Executives
Jamie Christensen officer: Sr. Vice President, Chief Scie C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Benjamin Hickey officer: EVP, Chief Commercial Officer C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Aaron Ondrey officer: Interim CFO 3545 CRAY COURT, SAN DIEGO CA 92121
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Christopher Fuglesang other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Shehan Bharatha Dissanayake other: See remarks 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Faheem Hasnain director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John B Moriarty officer: Chief Legal Officer ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Laurie Stelzer officer: CFO 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Julie M Cherrington director 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121

Mirati Therapeutics (Mirati Therapeutics) Headlines